Open Access

Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer

  • Authors:
    • Yue‑Nan Huang
    • Xin Guo
    • Liu‑Ping You
    • Chun‑Jing Wang
    • Jia‑Qi Liu
    • Yun‑Long Li
  • View Affiliations

  • Published online on: September 6, 2017     https://doi.org/10.3892/ol.2017.6899
  • Pages: 5229-5234
  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC) is one of the most common reasons for cancer‑associated mortality worldwide. The present study aimed to investigate the drug resistance mechanism of the oxaliplatin (OXA)‑resistant HT‑29 cell line (HT‑29/L‑OHP) and examine the expression of lysosome‑associated protein transmembrane 4β (LAPTM4β), a drug resistance‑associated gene. In the present study, a drug concentration gradient method was used to establish the drug‑resistant HT‑29/L‑OHP cell line. Cell apoptosis was analyzed by flow cytometry. LAPTM4β mRNA expression was examined by reverse transcription‑quantitative polymerase chain reaction analysis and LAPTM4β‑35 expression was examined by western blot analysis. Cell morphology of the HT‑29/L‑OHP drug‑resistant cell line was examined. The results indicated that the intercellular space among HT‑29 cells was small, with aggregative growth while the intercellular space among HT‑29/L‑OHP cells was large, with scattered growth. The apoptotic rate in HT‑29/L‑OHP cells (11.7%) was significantly lower compared with that in HT‑29 cells (17.7%) (P<0.05). LAPTM4β mRNA expression in HT‑29/L‑OHP cells was significantly increased compared with that in HT‑29 cells (P<0.05). The relative expression of LAPTM4β‑35 protein in HT‑29/L‑OHP cells was significantly higher compared with that inHT‑29 cells (P<0.05). In conclusion, LAPTM4β may be involved in the multidrug resistance processes of CRC. Therefore, LAPTM4β may serve as a novel biomarker for drug resistance of CRC.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 14 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang YN, Guo X, You LP, Wang CJ, Liu JQ and Li YL: Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer. Oncol Lett 14: 5229-5234, 2017
APA
Huang, Y., Guo, X., You, L., Wang, C., Liu, J., & Li, Y. (2017). Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer. Oncology Letters, 14, 5229-5234. https://doi.org/10.3892/ol.2017.6899
MLA
Huang, Y., Guo, X., You, L., Wang, C., Liu, J., Li, Y."Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer". Oncology Letters 14.5 (2017): 5229-5234.
Chicago
Huang, Y., Guo, X., You, L., Wang, C., Liu, J., Li, Y."Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer". Oncology Letters 14, no. 5 (2017): 5229-5234. https://doi.org/10.3892/ol.2017.6899